November 12, 2026

HeartBeam Reports Third Quarter 2026 Results

- *Redirected the Majority of Company Resources to Heart Attack Assessment, a Market Opportunity 4x Larger than the Arrhythmia Market*
- *Received FDA Breakthrough Device Designation for Heart Attack Assessment and Accepted into FDA's Total Product Life Cycle Advisory Program (TAP)*
- *Reported Positive ALIGN-ACS Pilot Study Results at TCT 2026 with HeartBeam Patient-Recorded ECG Demonstrating Higher Specificity Than Standard 12-Lead ECG for Heart Attack Assessment*
- *U.S. Pivotal Study for Heart Attack Assessment Planned to Begin in First Quarter of 2027*
- *Created Capital Efficiency with Focused Path to Heart Attack Assessment, Resulting in a 23% Reduction in Quarterly Operating Cash Outflows*
- *Management to Host Webcast and Conference Call Today at 4:30 p.m. ET*

SANTA CLARA, Calif.--(BUSINESS WIRE)-- **HeartBeam, Inc.** (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today reported its financial and operational results for the third quarter ended September 30, 2026.

Third Quarter & Subsequent 2026 Operational Highlights

In September 2026, the Company sharpened its strategy and directed the majority of its financial and personnel resources to heart attack assessment, which it views as its largest value-creation opportunity. Since then, HeartBeam has received FDA Breakthrough Device Designation, been accepted into FDA's TAP program, completed enrollment in HEADSTART-ACS, its largest heart attack assessment study to date, and reported positive pilot results from ALIGN-ACS at TCT 2026. The Company now plans to finalize the U.S. pivotal study design in the fourth quarter of 2026 and begin patient enrollment in the first quarter of 2027.

Heart Attack Assessment: *Strategic Focus*

- In September 2026, the Company announced it is redirecting the majority of its resources to heart attack (myocardial infarction, or MI) assessment.
- More than 20 million U.S. adults are at elevated risk of a heart attack, a population the Company estimates is approximately four times larger than the arrhythmia market.
- The Company estimates the MI opportunity at approximately $15 billion, within a broader cardiac platform opportunity exceeding $40 billion.

Regulatory Progress

- In October 2026, received FDA Breakthrough Device Designation for the HeartBeam System as a tool for assessing potential heart attacks at home.

- FDA granted the Breakthrough designation within 30 days of the Company's request, ahead of the agency's 60-day statutory review period.
- In October 2026, the HeartBeam System was accepted into FDA's Total Product Life Cycle Advisory Program (TAP), which provides dedicated FDA advisors and early engagement with payers, including the Centers for Medicare & Medicaid Services.
- In October 2026, the Company reached alignment with the FDA on a 510(k) pathway for the heart attack assessment indication.
- The Company plans to initiate its U.S. pivotal study in the first quarter of 2027 leveraging results from the ALIGN-ACS pilot study to finalize the design of the study in the fourth quarter of 2026.
- The U.S. pivotal study is intended to support a future FDA submission to expand the HeartBeam System's indication beyond arrhythmia assessment to include heart attack assessment.

Positive Pilot Study Results Presented at TCT 2026

- ALIGN-ACS pilot study results were presented by Graham Nichol, MD, MPH, FRCP(C), of the University of Washington, at TCT 2026 in San Diego.
- The study enrolled 132 adults at the emergency departments of two major cardiology centers in Belgrade, Serbia, and evaluated the diagnostic accuracy of the HeartBeam System compared with a standard 12-lead ECG in assessing acute coronary syndrome (ACS).
- Eight cardiologists, blinded to each patient's diagnosis, independently interpreted both HeartBeam and standard 12-lead ECG recordings. Interpretations were compared with each patient's final diagnosis as determined by an independent panel of three cardiologists.

Key findings:

- **Higher specificity, comparable sensitivity.** HeartBeam showed higher specificity than standard 12-lead ECG (81.8% vs. 71.4%) with comparable sensitivity (60.2% vs. 63.0%), pointing to its potential as a rule-in diagnostic aid.
- **Comparable sensitivity in STEMI assessment**. For ST-elevation myocardial infarction, the most time-sensitive form of heart attack, sensitivity was 82.9% for HeartBeam vs. 83.8% for standard 12-lead ECG.
- **More consistent interpretation.** Cardiologists agreed more often when reading HeartBeam recordings (Fleiss' kappa 0.73 vs. 0.54 for standard 12-lead ECG).
- **Patient ease of use**. 100% of patients recorded their own HeartBeam ECG under clinical supervision with no prior training, supporting potential use outside traditional clinical settings.

Growing Body of Clinical Evidence

- In October 2026, completed enrollment ahead of schedule in HEADSTART-ACS, the largest heart attack assessment study to date using HeartBeam technology.
- The study enrolled 486 emergency department patients with chest pain at the National Cardiovascular Center Harapan Kita in Jakarta, Indonesia.
- Indonesia, the world's fourth most populous country, represents a strategically significant market of 288 million people.
- Together with ALIGN-ACS, the Company now has clinical experience with more than

600 patients in heart attack assessment.
- In October 2026, joined the EU-co-funded EXIT-CVD research consortium as a contributing partner, alongside Philips, Medtronic, GE HealthCare and other global healthcare organizations.
- HeartBeam will lead the HEART-CHECK study, one of EXIT-CVD's 22 clinical studies, evaluating the HeartBeam System for early detection and triage of cardiac events in high-risk patients recently discharged after an acute coronary syndrome.

Other Operational Highlights:

- In July 2026, HeartBeam was awarded a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into the Company’s existing ECG hardware platform, supporting future applications in structural heart disease and heart failure monitoring. The Company’s patent portfolio includes 26 issued patents worldwide.
- Cash and cash equivalents totaled $6.1 million as of September 30, 2026, compared to $4.4 million as of December 31, 2025. Net cash used in operating activities was $2.6 million for the third quarter of 2026, a 23% decrease compared to the second quarter of 2026 and an 18% decrease compared to the third quarter of 2025.

Management Commentary

"The third quarter marked a decisive turn for HeartBeam," said Richard Ferrari, Executive Chairman. "We committed the majority of our resources to heart attack assessment, and the milestones have quickly followed. In just the last six weeks, we received FDA Breakthrough Device Designation, were accepted into FDA's TAP program, and aligned with the FDA on a 510(k) submission pathway for a heart attack assessment indication. We also completed enrollment in HEADSTART-ACS ahead of schedule and presented positive results from the ALIGN-ACS pilot study at TCT showing higher specificity than the standard 12-lead ECG. With clinical experience in more than 600 patients and no new hardware required, we are focused on beginning our U.S. pivotal study in the first quarter of 2027."

Branislav Vajdic, Ph.D., Founder and President of HeartBeam, added, “Today, a person with chest pain at home has no reliable way to know whether it is a heart attack, and that uncertainty results in delays and potentially worse outcomes. Our goal is to shorten the time between the first sign of symptoms and the decision to seek care, by giving patients and their physicians clinical-grade cardiac information when every minute matters. We believe HeartBeam can help close that gap for the millions of people at risk.”

Third Quarter 2026 Financial Results

Selling, general and administrative expenses for the third quarter of 2026 were $1.3 million, compared to $2.0 million for the third quarter of 2025, a decrease of 33%. The decrease in SG&A expense of $0.7 million is primarily related to a decrease in non-cash stock-based compensation expense of $0.4 million and a reduction in employee costs of $0.3 million driven by lower headcount period over period.

Research and development expenses for the third quarter of 2026 were $2.1 million, compared to $3.3 million for the third quarter of 2025, a decrease of 35%. The decrease in R&D expense is primarily related to the completion of product development and consulting

costs related to the HeartBeam System and a prototype patch device of $0.8 million, completion of enrollment in the ALIGN-ACS pilot study of $0.3 million, and a decrease in headcount-related costs of $0.1 million.

Total operating expenses for the third quarter of 2026 were $3.5 million, compared to $5.3 million for the third quarter of 2025.

Net loss for the third quarter of 2026 was $3.0 million, or $(0.05) per basic and diluted share, compared to a net loss of $5.3 million, or $(0.15) per basic and diluted share, for the third quarter of 2025.

Net cash used in operating activities was $2.6 million for the third quarter of 2026, a 23% decrease compared to the second quarter of 2026 and an 18% decrease compared to the third quarter of 2025. Net cash used in operating activities was $9.5 million for the nine months ended September 30, 2026, compared to $11.1 million for the nine months ended September 30, 2025, a decrease of 14%.

Cash and cash equivalents totaled $6.1 million as of September 30, 2026, compared to $4.4 million as of December 31, 2025. In August 2026, the Company entered into an at-the-market sales agreement (the “ATM”) with Titan Partners Securities LLC, as sales agent, pursuant to which the Company may sell, from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $25.0 million. In the fourth quarter of 2026 through the date of this release, the Company raised net proceeds of approximately $4.0 million. Giving effect to these net proceeds, the Company’s pro forma cash and cash equivalents as of September 30, 2026, would have been approximately $10.1 million.

Financial Outlook

- Third quarter 2026 operating cash outflow was lower than in the second quarter of 2026 as a result of the Company’s reduced cost structure and the capital efficiency created by the focused path to heart attack assessment.
- As outlined previously, the baseline fourth quarter 2026 operating cash outflow is expected to be below $2.5 million; accelerated U.S. pivotal study timing would add to fourth quarter spending.
- Full year 2026 net operating cash outflow is now expected to be between $12.0 million and $12.5 million, a further reduction from the Company’s previous guidance.
- The Company expects its cash runway to extend further into 2027, aligned with the achievement of key milestones.

Third Quarter 2026 Results Conference Call

HeartBeam Executive Chairman Richard Ferrari, Founder and President Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here.

To access the call, please use the following information:

Date:	Thursday, November 12, 2026
Time:	4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-in:	1-877-704-4453
International Dial-in:	1-201-389-0920
Conference Code:	13763268
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1779198&tp_key=0e699c3be5

A telephone replay will be available approximately three hours after the call and will run through November 26, 2026, by dialing 1-844-512-2921 from the U.S. and Canada, or 1-412-317-6671 from international locations, and entering replay pin number: 13763268. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company's investor relations section here.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025.[1] The technology is currently being studied for heart attack assessment and is considered investigational in that indication. The Company holds over 25 issued patents worldwide related to technology enablement. For additional information, visit HeartBeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

[1]**Cleared Indications for Use**
The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment only. The technology's use for heart attack assessment is investigational and not FDA cleared. For full details on the intended use of the HeartBeam technology, refer to the Company's Cleared Indications for Use and full instructions at https://www.heartbeam.com/indications.

MKT-179 v0

HEARTBEAM, INC.
Condensed Balance Sheets (Unaudited)
(In thousands, except share data)

	September 30, 2026	December 31, 2025
Assets		
Current Assets:		
Cash and cash equivalents	$ 6,065	$ 4,380
Prepaid expenses and other current assets	120	202
Inventory	114	103
Total Current Assets	6,299	4,685
Property and equipment, net	1,516	1,102
Other assets	57	56
Total Assets	$ 7,872	$ 5,843
Liabilities and Stockholders' Equity		
Current Liabilities:		
Accounts payable (includes related party $5 and $5, respectively)	$ 267	$ 1,053
Accrued expenses (includes related party $5 and $0, respectively)	1,091	2,187
Total Current Liabilities	1,358	3,240
Total Liabilities	1,358	3,240
Commitments and Contingencies (Note 8)		
Stockholders' Equity		
Preferred stock - $0.0001 par value; 10,000,000 shares authorized; 0 shares outstanding at September 30, 2026 and December 31, 2025	$ —	$ —
Common stock - $0.0001 par value; 100,000,000 shares authorized; 57,513,001 and 40,117,404 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	6	4
Additional paid in capital	96,545	79,887
Accumulated deficit	(90,037)	(77,288)
Total Stockholders' Equity	6,514	2,603
Total Liabilities and Stockholders' Equity	$ 7,872	$ 5,843

HEARTBEAM, INC.
Condensed Statements of Operations (Unaudited)
(In thousands, except share and per share data)

	Three months ended September 30,		Nine months ended September 30,	
	2026	**2025**	**2026**	**2025**
Operating Expenses:				
Selling, general and administrative	$ 1,339	$ 2,012	$ 6,449	$ 5,733
Research and development	2,118	3,278	6,816	10,096
Total operating expenses	3,457	5,290	13,265	15,829
Loss from operations	(3,457)	(5,290)	(13,265)	(15,829)
Other Income and (Expense)				
Interest income	63	36	135	117
Other income, net	384	(1)	381	(1)
Total other income	447	35	516	116
Loss before provision for income taxes	(3,010)	(5,255)	(12,749)	(15,713)
Income tax provision	—	—	—	—
Net Loss	$ (3,010)	$ (5,255)	$ (12,749)	$ (15,713)
Net loss per share, basic and diluted	$ (0.05)	$ (0.15)	$ (0.25)	$ (0.48)
Weighted average common shares outstanding, basic and diluted	57,204,402	34,396,431	50,242,536	32,928,884

HEARTBEAM, INC.
Condensed Statements of Cash Flows (Unaudited)
(In thousands)

	Nine months ended September 30,	
	2026	**2025**
Cash Flows From Operating Activities		
Net loss	$ (12,749)	$ (15,713)
Adjustments to reconcile net loss to net cash used in operating activities		
Depreciation	150	23
Stock based compensation expense	3,855	3,720
Stock issuance upon vesting of restricted stock units	915	—
Stock issuance for services	100	—
Changes in operating assets and liabilities:		
Prepaid expenses and other current assets	82	123
Inventory	(11)	—
Accounts payable and accrued expenses	(1,882)	765
Net cash used in operating activities	**(9,540)**	**(11,082)**
Cash Flows From Investing Activities		
Purchase of property and equipment	(564)	(184)
Purchase of short-term investments	—	3,760
Maturities of short-term investments	—	(3,760)
Net cash used in investing activities	**(564)**	**(184)**
Cash Flows From Financing Activities		
Proceeds from sale of equity, net of issuance costs	10,265	10,250
Proceeds from sale of equity under ATM, net of issuance costs	1,515	494
Proceeds from exercise of stock options	10	1
Net cash provided by financing activities	**11,790**	**10,745**
Net increase / (decrease) in cash and restricted cash	1,686	(521)
Cash, cash equivalents and restricted cash – Beginning of period	**4,436**	**2,433**
Cash, cash equivalents and restricted cash – Ending of period	**$ 6,122**	**$ 1,912**
Reconciliation of cash, cash equivalents and restricted cash:		
Cash and cash equivalents	$ 6,065	$ 1,856
Restricted cash (included in other assets)	57	56
Total cash, cash equivalents and restricted cash	**$ 6,122**	**$ 1,912**
Supplemental Disclosures of Cash Flow Information:		
Purchase of property and equipment in accounts payable	$ —	$ 83
Taxes paid	$ —	$ —

View source version on businesswire.com:
https://www.businesswire.com/news/home/20261112561877/en/

Media Contact:
media@heartbeam.com

Investor Relations Contact:
Chris Tyson

Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

Source: HeartBeam, Inc.